NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CLDX

Celldex Therapeutics Inc

Jul 15 • 04:00PM ET

22.85

Dollar change -0.51
Percentage change -2.18	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK REGN GILD VRTX INCY AMGN BIIB JNJ PFE

| Held by: VTI IWM VXF XBI IWN SCHA VTWO VHT ITOT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.70	Insider Own	2.84%	Shs Outstand	66.38M	Perf Week	7.13%
Market Cap	1.52B	Forward P/E	-	EPS next Y	-4.02	Insider Trans	0.00%	Shs Float	64.51M	Perf Month	12.29%
Enterprise Value	853.25M	PEG	-	EPS next Q	-0.86	Inst Own	110.76%	Short Float	12.21%	Perf Quarter	35.69%
Income	-178.85M	P/S	200.68	EPS this Y	-40.83%	Inst Trans	-4.88%	Short Ratio	8.04	Perf Half Y	-6.16%
Sales	7.56M	P/B	2.16	EPS next Y	-16.43%	ROA	-22.24%	Short Interest	7.87M	Perf YTD	-9.58%
Book/sh	10.59	P/C	2.27	EPS next 5Y	-16.47%	ROE	-23.20%	52W High	47.00 -51.38%	Perf Year	-40.53%
Cash/sh	10.05	P/FCF	-	EPS past 3/5Y	-14.23% 6.91%	ROIC	-25.37%	52W Low	14.40 58.68%	Perf 3Y	-14.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.71% 14.46%	Gross Margin	56.75%	Volatility	4.73% 6.50%	Perf 5Y	88.07%
Dividend TTM	-	EV/Sales	112.86	EPS Y/Y TTM	5.14%	Oper. Margin	-2873.52%	ATR (14)	1.26	Perf 10Y	-94.08%
Dividend Ex-Date	-	Quick Ratio	21.67	Sales Y/Y TTM	24.49%	Profit Margin	-2366.07%	RSI (14)	60.23	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	21.67	EPS Q/Q	-45.42%	SMA20	6.55%	Beta	1.22	Target Price	58.54
Payout	-	Debt/Eq	0.00	Sales Q/Q	345.51%	SMA50	11.08%	Rel Volume	0.97	Prev Close	23.36
Employees	186	LT Debt/Eq	0.00	Earnings	May 08 AMC	SMA200	-1.60%	Avg Volume	979.80K	Price	22.85
IPO	May 15, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.28% -30.33%	Trades		Volume	945,954	Change	-2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	Canaccord Genuity	Buy	$64
Mar-20-25	Initiated	Morgan Stanley	Overweight	$46
Feb-13-25	Initiated	UBS	Buy	$44
Oct-07-24	Initiated	Citigroup	Buy	$70
Sep-30-24	Initiated	Goldman	Neutral	$45
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy	$58
Jun-11-24	Initiated	Wolfe Research	Outperform	$51
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$27
Aug-22-23	Initiated	Wells Fargo	Underweight	$21
Sep-17-21	Initiated	Jefferies	Buy	$66
Sep-10-21	Initiated	SVB Leerink	Outperform	$68
Jul-22-21	Initiated	Guggenheim	Buy	$66
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight	$8
Aug-01-17	Resumed	H.C. Wainwright	Buy	$10
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral	$4
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform

Show Previous Ratings

Jun-24-25 01:01AM	CLDX- A Promising Biotech Name Targeting CSU (MoneyShow) +6.18%
Jun-14-25 10:48AM	Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 (GlobeNewswire)
Jun-12-25 06:01PM	Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-10-25 04:01PM	Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress (GlobeNewswire)
08:01AM	Loading…
Jun-06-25 08:01AM	Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors (GlobeNewswire) +9.32%
May-09-25 10:34AM	Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey) -6.10%
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:14PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-25 04:01PM	Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease (GlobeNewswire) -9.31%
Apr-22-25 07:40AM	Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (Seeking Alpha)
Mar-24-25 03:24PM	Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? (Zacks) +5.80%
Mar-20-25 11:44AM	Celldex a new overweight at Morgan Stanley on urticaria candidate (SeekingAlpha)
Mar-04-25 08:01AM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
08:01AM	Loading…
Mar-03-25 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 (GlobeNewswire) -5.93%
Mar-01-25 12:45PM	Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 (GlobeNewswire)
Feb-27-25 05:30PM	Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:32PM	Celldex: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Dec-19-24 08:01AM	Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis (GlobeNewswire)
Nov-20-24 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases (GlobeNewswire) +5.68%
Nov-11-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 05:30PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.65%
04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 12:05PM	Celldex selloff creates buying opportunity, says Guggenheim (TipRanks)
Oct-26-24 05:43PM	Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire)
Oct-25-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 (GlobeNewswire)
Oct-23-24 08:39AM	Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results (Insider Monkey)
06:10PM	Loading…
Oct-15-24 06:10PM	Celldex Therapeutics, Inc. (CLDX): Hedge Funds Hidden Gem in Small-Cap Stocks (Insider Monkey)
Sep-25-24 10:45AM	Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 (GlobeNewswire) -12.06%
Sep-16-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 (GlobeNewswire)
Sep-14-24 05:18PM	Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-12-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.77%
Aug-08-24 05:25PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:01PM	Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire) -5.77% -8.45%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 08:01AM	Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jun-11-24 07:00PM	Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ... (GuruFocus.com)
Jun-04-24 04:01PM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-02-24 09:01AM	Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 (GlobeNewswire)
May-27-24 09:55AM	Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet (Zacks)
May-15-24 11:33AM	Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study (MT Newswires)
08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis (GlobeNewswire)
May-09-24 09:55AM	Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade (Zacks)
May-06-24 09:55PM	CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:22PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-24 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria (GlobeNewswire)
Apr-09-24 09:35AM	Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Apr-08-24 12:00PM	All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy (Zacks)
09:35AM	Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Mar-20-24 09:55AM	Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect? (Zacks)
Mar-08-24 07:00AM	Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 10:30AM	Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
10:10AM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-29-24 09:14PM	Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock (GlobeNewswire) -6.44% +7.95%
12:00PM	Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know (Zacks)
Feb-28-24 04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-26-24 04:03PM	Celldex Stock Rockets 28% On A Promising New Hives Treatment (Investor's Business Daily) +27.76% +5.83%
12:11PM	Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment (Investor's Business Daily)
08:10AM	Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:19AM	Celldex: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-24-24 02:05PM	Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
Feb-20-24 08:26AM	TipRanksPerfect 10 List: These 2 Biotech Stocks Look Compelling at Current Levels (TipRanks)
Feb-06-24 04:01PM	Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-05-24 08:01AM	Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 (GlobeNewswire)
Nov-27-23 04:15PM	Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace)
Nov-07-23 11:15PM	Celldex Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -8.68%
04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-23 06:47PM	Why Celldex Therapeutics Blasted 13% Higher on Monday (Motley Fool) +12.97%
04:01PM	Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi (Investor's Business Daily)
12:15PM	Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall, Monday, 11/6/2023 (Associated Press)
07:00AM	Celldexs reinvention advances with inflammatory disease drug data (BioPharma Dive)
06:30AM	Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-05-23 03:00PM	Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab (GlobeNewswire)
Nov-04-23 05:39AM	Celldex Therapeutics Inc (CLDX) Q3 2023 Earnings: R&D Expenses Rise Amid Progress in ... (GuruFocus.com)
Nov-02-23 04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance) +8.20%
04:01PM	Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-26-23 07:01AM	Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023 (GlobeNewswire)
Sep-25-23 08:31AM	Celldex Therapeutics to Present at Cantor Global Healthcare Conference (GlobeNewswire)
Aug-22-23 09:35AM	AppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls (The Fly) -5.20%
Aug-08-23 05:30PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.83%
04:21PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-11-23 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jul-06-23 08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (GlobeNewswire)
Jun-10-23 10:45AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 (GlobeNewswire)
Jun-08-23 04:01PM	Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 (GlobeNewswire)
Jun-02-23 08:01AM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies (GlobeNewswire)
May-23-23 06:10AM	Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-15-23 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023 (GlobeNewswire)

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marucci Anthony S	PRESIDENT & CEO	Nov 11 '24	Buy	26.82	11,500	308,430	40,284	Nov 12 08:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDX

Celldex Therapeutics Inc

Upgrade your FINVIZ experience